Article Sidebar

PDF
Date Published: 05/01/2024
Abstract Views: 115
Views PDF: 86
DOI: https://doi.org/10.51298/vmj.v533i1B.7813
Issue
Vol. 533 No. 1B (2023)
Section
Các bài báo
How to Cite
Nguyễn , T. T. H. ., Đỗ , H. N., Đỗ , A. T. ., & Hoàng , D. H. . (2024). THE EFFECT OF CONCURRENT CHEMORADIOTHERAPY FOLLOWED BY VIDL CHEMOTHERAPY IN EXTRANODAL NK/T-CELL LYMPHOMA, NASAL TYPE IN K. Vietnam Medical Journal, 533(1B). https://doi.org/10.51298/vmj.v533i1B.7813

THE EFFECT OF CONCURRENT CHEMORADIOTHERAPY FOLLOWED BY VIDL CHEMOTHERAPY IN EXTRANODAL NK/T-CELL LYMPHOMA, NASAL TYPE IN K

Thị Thu Hường Nguyễn , Huyền Nga Đỗ , Anh Tú Đỗ , Dương Huy Hoàng

Main Article Content

Abstract

We conducted performed a descriptive study on a series of cases to evaluate the effectiveness of VIDL regimen after concurrent chemoradiaotherapy with cisplatin in stage IE/IIE nasal extranodal T/NK cell lymphoma. Concurrent chemoradiotherapy yielded a 66,67% complete response rate, 26,67% partial response rate; common adverse effects were dermatitis and oral mucositis. After concurrent chemoradiotherapy, VIDL showed 86,67% complete response rate, 13,33% partial response rate. Hematologic toxicity was frequent during VIDL chemotherapy (grades III/IV 13,33%), no treatment-relates mortality was observed. PFS and OS at 1 year were 100%. In conclusion, concurrent chemoradiaotherapy followed by VIDL is a feasible treatment for stages IE/IIE nasal extranodal T/NK cell lymphoma.

Article Details

References

1. Bassig BA, Au WY, Mang O, et al. Subtype-specific incidence rates of lymphoid malignancies in Hong Kong compared to the United States, 2001-2010. Cancer Epidemiol 2016;42:15-23.
2. Egashira M, Kawamata N, Sugimoto K, et al. P-glycoprotein expression on normal and abnormally expanded natural killer cells and inhibition of P-glycoprotein function by cyclosporin A and its analogue, PSC833. Blood 1999;93:599-606
3. Kim SJ, Yang DH, Kim JS, et al. Concurrent chemoradiotherapy followed by L-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma: CISL08-01 phase II study. Ann Hematol 2014;93:1895-901.
4. Kim SJ, Kim K, Kim BS, et al. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: consortium for Improving Survival of Lymphoma study. J Clin Oncol 2009;27:6027-32.
5. Kim SJ, Yang DH, Kim JS, et al. Concurrent chemoradiotherapy followed by L-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma: CISL08-01 phase II study. Ann Hematol 2014;93:1895-901.
6. ShanShan Bu, Fangfang Yuan, Xudong Wei, et al. L-asparaginase-based regimen as a first-line treatment for newly diagnosed nasal type extranodal natural killer cell/T-cell lymphoma. Exp Ther Med. 2016;11(6):2437-2445
7. Yamaguchi M et al. Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. Journal of Clinical Oncology. 2009;27(33):5594-5600